Chemical Classification: Synthetic pentasaccharide anticoagulant
CAS Number: 114870-03-0
Molecular Formula: C31H53N3Na10O49S8 (Note: The exact molecular weight may vary slightly depending on the source)
Storage Conditions: Store at -20°C under an inert gas atmosphere to maintain stability.
Pharmacological Characteristics:
Mechanism of Action: Fondaparinux Sodium is a highly selective and indirect inhibitor of factor Xa, acting through antithrombin III. It prevents blood coagulation and inhibits thrombus formation.
Pharmacokinetics: It exhibits linear, dose-dependent pharmacokinetics, providing a highly predictable response. It has a rapid onset of action and a half-life of 14 to 16 hours, providing sustained antithrombotic activity for 24 hours.
Clinical Applications:
Indications: Primarily used for the prevention of venous thromboembolic events (VTE) in patients undergoing orthopedic surgery, particularly hip fracture surgery, major knee surgery, or hip replacement surgery.
Route of Administration: Administered by intravenous infusion or subcutaneous injection.
Precautions and Warnings:
Contraindications: Hypersensitivity to fondaparinux sodium or any of its excipients, clinically significant active bleeding, acute bacterial endocarditis, and severe renal impairment with creatinine clearance <20 mL/min.
Drug Interactions: Avoid concomitant use with drugs that increase the risk of bleeding, such as desirudin, fibrinolytic agents, and GPIIb/IIIa receptor antagonists.
Development History and Market Prospects:
Development History: Fondaparinux sodium is the first and only synthetic heparin-like pentasaccharide anticoagulant. It was approved in 2001 under the brand name Arixtra.
Market Prospects: Due to its excellent therapeutic efficacy and strong market potential, fondaparinux sodium has long been of interest to medicinal chemists and synthetic chemists. It occupies an important position in the anticoagulant drug market, particularly in the prevention of venous thromboembolic events.
